Avrobio Contact Number

All Time Past 24 Hours Past Week Past month Post Your Comments?

Listing Results Avrobio Contact Number

Contact Us – AVROBIO

5 hours ago Avrobio.com Show details

617.914.8420

Our headquarters: One Kendall Square Building 300, Suite 201 Cambridge, MA 02139, USA Phone: 617.914.8420 GPS: 15 Hampshire Street, Cambridge, MA

Category: Contact SupportShow more

Avrobio Crunchbase Company Profile & Funding

7 hours ago Crunchbase.com Show details

(617) 914 8420

Phone Number (617) 914 8420 Avrobio is a clinical stage company developing step-change cell and gene therapies targeting cancer and rare disease. The catalyst for creating Avrobio is to accelerate scientific breakthroughs related to the convergence of cell and gene therapies.

Founded: 2015
Founder: Jeffrey Medin

Category: Contact NumberShow more

AVROBIO – LentiviralBased Gene Therapy

4 hours ago Avrobio.com Show details

AVROBIO to Participate at Four Upcoming Investor Conferences. CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Sep. 1, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in

Category: Contact NumberShow more

Gaucher Disease Clinical Trial AVROBIO

6 hours ago Avrobiogauchertrial.com Show details

877-330-5214

and. Talk to your doctor or a stem cell transplant specialist about the potential risks and benefits of participating in an investigational gene therapy trial. Complete Form. Clinical trials in your region. United States. Australia. Find Local Number. US 1-877-330-5214. AUS 1800-853-166.

Estimated Reading Time: 5 mins

Category: Contact NumberShow more

SEC Filing : AVROBIO

4 hours ago Investors.avrobio.com Show details

617-914-8420

AVROBIO, Inc. Street Address 1 Street Address 2; ONE KENDALL SQUARE: BLDG. 300, SUITE 201: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02139: 617-914-8420

Category: Contact NumberShow more

About Us – AVROBIO

8 hours ago Avrobio.com Show details

We are AVROBIO. Transforming patients' worlds. We strive to give people with lysosomal disorders freedom for life through gene therapies designed to halt or reverse disease with a single dose. Gene therapy for the entire body. Our goal is simple and powerful: We aim to enable individuals with genetic disease to live longer — free from disease

Category: Contact NumberShow more

Patient Early Access Policy – AVROBIO

3 hours ago Avrobio.com Show details

Patient Early Access Policy. AVROBIO is committed to developing gene therapies that have the potential to transform the treatment of rare diseases. To accomplish this, we collaborate with many researchers, individuals living with genetic disorders, patient groups and physicians and we work closely with regulatory agencies.

Category: Contact NumberShow more

Our Leadership – AVROBIO

2 hours ago Avrobio.com Show details

Our leadership team moves in one direction: forward. Our focus unites the world-class experts we have brought together across cell and gene therapy, rare disease, clinical development and manufacturing. We share a passion for science, a commitment to teamwork and, above all, dedication to families and individuals living with genetic diseases.

Category: Contact NumberShow more

Avrobio Email Format avrobio.com Emails

Just Now Rocketreach.co Show details

Avrobio Email Format. Avrobio uses 2 email formats, with first '.' last (ex. [email protected]avrobio.com) being used 93.9% of the time. Get Verified Emails for Avrobio Employees. Avrobio's Email Format.

Category: Contact NumberShow more

EIN 810710585 Avrobio, Inc., Cambridge, Massachusetts

5 hours ago Eintaxid.com Show details

Avrobio, Inc. is a corporation in Cambridge, Massachusetts. The employer identification number (EIN) for Avrobio, Inc. is 810710585. EIN for organizations is sometimes also referred to as taxpayer identification number or TIN or simply IRS Number. It is one of the corporates which submit 10-K …

Category: Contact NumberShow more

The plato® Platform – AVROBIO

9 hours ago Avrobio.com Show details

The plato ® platform includes: A lentiviral vector and proprietary tags designed to optimize vector copy number, transduction efficiency and resulting enzyme/protein activity in target cells. Advanced cryopreservation to extend shelf life and enable flexible scheduling for patients and healthcare providers. A personalized conditioning regimen

Category: Contact NumberShow more

Job Openings – AVROBIO

9 hours ago Avrobio.com Show details

The PV Operations Lead manages PV activities globally across all AVROBIO products in clinical development and on the market. Specifically, the Operations lead (1) supports operational aspects of the PV system, (2) collaborates with cross-functional partners to facilitate the development of comprehensive plans, and (3) coordinates the execution

Category: Contact NumberShow more

AVROBIO Announces the Appointment of Kim Raineri as Chief

6 hours ago Investors.avrobio.com Show details

339-970-2843

Investor Contact: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] Media Contact: Tom Donovan Ten Bridge Communications 857-559-3397 [email protected] Source: AVROBIO, Inc.

Category: Contact NumberShow more

AVROBIO Presents Positive Initial Data for its

3 hours ago Investors.avrobio.com Show details

339-970-2843

Source: AVROBIO, Inc. Investor Contact: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] Media Contact: Tom Donovan Ten Bridge Communications 857-559-3397 [email protected]

Category: Contact NumberShow more

AVROBIO, Inc. Reports Third Quarter 2019 Financial Results

5 hours ago Investors.avrobio.com Show details

339-970-2843

Source: AVROBIO, Inc. Investor Contact: Christopher F. Brinzey Westwicke, and ICR Company 339-970-2843 [email protected] Media Contact: Tom Donovan 857-559-3397 Ten Bridge Communications [email protected]

Category: Contact NumberShow more

AVROBIO Announces Inducement Grants Under Nasdaq Listing

9 hours ago Investors.avrobio.com Show details

339-970-2843

Investor Contact: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] . Media Contact: Stephanie Simon Ten Bridge Communications 617-581-9333 [email protected] Source: AVROBIO, Inc.

Category: Contact NumberShow more

AVRO AVROBIO Inc. • BioPharmCatalyst

5 hours ago Biopharmcatalyst.com Show details

AVROBIO, Inc. (NASDAQ: AVRO ), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Thursday, June 17, 2021. A live webcast of the presentation can

Category: Contact NumberShow more

AVROBIO hiring Executive Director, Global Regulatory Lead

8 hours ago Linkedin.com Show details

ABOUT AVROBIO. Our vision is to bring personalized gene therapy to the world. Contact info Email address. Please enter a valid answer OMB Control Number 1250-0005 Expires 05/31/2023. Why

Category: Contact NumberShow more

Avrobio Company Profile Office Locations, Competitors

4 hours ago Craft.co Show details

Avrobio has 1.68k Twitter Followers. The number of followers has increased 1.2% month over month and increased 5.6% quarter over quarter

Category: Contact NumberShow more

Avrobio Funding, Financials, Valuation & Investors

6 hours ago Crunchbase.com Show details

Avrobio has raised a total of $85M in funding over 3 rounds. Their latest funding was raised on Feb 1, 2018 from a Series B round. Avrobio is registered under the ticker NASDAQ:AVRO . Their stock opened with $19.00 in its Jun 20, 2018 IPO. Avrobio is funded by 10 investors.

Category: Contact NumberShow more

EX99.1

4 hours ago Sec.gov Show details

339-970-2843

AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investor Contact: Christopher F. Brinzey . Westwicke, an ICR Company . 339-970-2843. [email protected] Media Contact: Kit Rodophele . Ten Bridge Communications . [email protected]

Category: Contact NumberShow more

AVROBIO, Inc. Reports Second Quarter 2018 Financial

6 hours ago Investors.avrobio.com Show details

617-914-8413

AVROBIO, Inc. 617-914-8413 [email protected] Christopher F. Brinzey Westwicke Partners 339-970-2843 [email protected] Media Contact: Kathryn Morris The Yates Network 914-204-6412 [email protected] CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands, except share data) (Unaudited)

Category: Contact NumberShow more

AVROBIO Reports Second Quarter 2021 Financial Results and

2 hours ago Investors.avrobio.com Show details

Second Quarter 2021 Financial Results. AVROBIO reported a net loss of $31.4 million for the second quarter of 2021 as compared to a net loss of $28.8 million for the comparable period in 2020. This increase was driven by increased research and development expenses as well as increased general and administrative expenses.

Category: Contact NumberShow more

AVROBIO Announces Inducement Grants Under Nasdaq Listing

7 hours ago Us.acrofan.com Show details

339-970-2843

AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contacts. Investor Contact: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] Media Contact: Kit Rodophele Ten Bridge Communications [email protected]

Category: Contact NumberShow more

AVROBIO Announces Inducement Grants Under Nasdaq Listing

3 hours ago Stocktitan.net Show details

339-970-2843

Investor Contact: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] Media Contact: Kit Rodophele Ten Bridge Communications [email protected] Source: AVROBIO, Inc.

Category: Contact NumberShow more

AVROBIO to Present New Clinical and Preclinical Data

7 hours ago Us.acrofan.com Show details

Any forward-looking statements in this press release are based on AVROBIO’s current expectations, estimates and projections about our industry as well as management’s current beliefs and expectations of future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially

Category: Contact NumberShow more

AVROBIO : ASGCT 2020 Fabry & Cystinosis Data Update

6 hours ago Marketscreener.com Show details

35. ASGCT 2020 data update - key takeaways. New data show consistent results across Fabry disease and cystinosis programs. Long-term Fabry patient data. Sustained long-term positive trends. • Patient 1 in the Phase 2 trial continues to show stable leukocyte and plasma AGA enzyme activity, now out 22 months. • Patient 3 in the Phase 2 trial

Category: Contact NumberShow more

AVROBIO, Inc. (AVRO) Company Profile & Facts Yahoo Finance

5 hours ago Finance.yahoo.com Show details

See the company profile for AVROBIO, Inc. (AVRO) including business summary, industry/sector information, number of employees, business summary, corporate governance, key executives and their

Category: Contact NumberShow more

Avrobio Company Profile: Stock Performance & Earnings

8 hours ago Pitchbook.com Show details

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher

Category: Contact NumberShow more

AVROBIO Announces Inducement Grants Under Nasdaq Listing

7 hours ago Finance.yahoo.com Show details

CAMBRIDGE, Mass., October 05, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced

Category: Contact NumberShow more

AVROBIO Announced Inducement Grants Under Nasdaq Listing

4 hours ago Biospace.com Show details

CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVROBIO (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 201,750 shares of the company’s common stock to eight new employees as inducement …

Category: Contact NumberShow more

AVROBIO Announces Inducement Grant Under Nasdaq Listing

6 hours ago Businesswire.com Show details

339-970-2843

Investor Contact: Christopher F. Brinzey Westwicke, an ICR Company 339-970-2843 [email protected] Media Contact: Stephanie Simon Ten Bridge Communications 617-581-9333 stephanie

Category: Contact NumberShow more

AVROBIO Reports Second Quarter 2021 Financial Results and

1 hours ago Finance.yahoo.com Show details

AVROBIO reported a net loss of $31.4 million for the second quarter of 2021 as compared to a net loss of $28.8 million for the comparable period in …

Category: Contact NumberShow more

AVROBIO : Announces Inducement Grants Under Nasdaq Listing

7 hours ago Marketscreener.com Show details

339-970-2843

AVROBIO explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Contact: Investor. Christopher F. Brinzey. Westwicke. ICR Company. T: 339-970-2843. E: [email protected] (C) 2021 Electronic News Publishing, source ENP Newswire

Category: Contact NumberShow more

Erik Ostrowski CFO of Avrobio AVRO

1 hours ago Cdn-macroaxis.netdna-ssl.com Show details

However, Avrobio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide.

Category: Contact NumberShow more

AVROBIO : Announces Inducement Grants Under Nasdaq Listing

9 hours ago Marketscreener.com Show details

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an aggregate of 83,750 shares of the company’s common stock to four new employees as inducement awards under the company’s 2019 Inducement …

Category: Contact NumberShow more

AVROBIO LinkedIn

Just Now Linkedin.com Show details

AVROBIO’s vision is to bring personalized gene therapy to the world. We aim to prevent, halt or reverse disease throughout the body with a single dose of gene therapy designed to drive durable

Category: Contact NumberShow more

Anup Agarwal Associate Director Manufacturing

4 hours ago Linkedin.com Show details

Aug 2014 - Jun 20183 years 11 months. Lexington, MA, USA. Post-approval lifecycle management of internally and externally manufactured commercial products using QbD principles. > Provided

Title: Process Development | MSAT | …
Location: Cambridge, Massachusetts, United States
1. 500+ connections

Category: Contact NumberShow more

AVROBIO Announces Inducement Grant Under Nasdaq Listing

6 hours ago Finance.yahoo.com Show details

AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted a …

Category: Contact NumberShow more

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from S&P

7 hours ago Marketscreener.com Show details

AVROBIO, INC. : Other Events, Financial Statements and Exhibits (form 8-K) AVROBIO : Management's Discussion and Analysis of Financial Condition and Results of Opera.. Analyst Recommendations on AVROBIO, INC. AVROBIO : Morgan Stanley Adjusts Price Target on AVROBIO to $29 From $31, Maintains Overwe..

Category: Contact NumberShow more

AVROBIO : Corporate Presentation August 2021 MarketScreener

1 hours ago Marketscreener.com Show details

A U G U S T 2 0 2 1. Disclaimer. This presentation has been prepared by AVROBIO, Inc. ("AVROBIO") for informational purposes only and not for any other. purpose. Certain information contained in this presentation and statements made orally during this presentation relate to or are based on studies, publications, surveys and other data obtained

Category: Contact NumberShow more

AVROBIO Inc. (AVRO): The stock medium term indicators show

8 hours ago Baxterreport.com Show details

The total number of common shares currently owned by the public is 42.51 million. AVRO does have institutional investors; and they hold 86.70% of the stock. AVROBIO Inc. – Insider Activity and Holdings. Moreover, the latest SEC filings also revealed that stock came across 1 new insider purchases involving 4,800 shares.

Category: Contact NumberShow more

Avrobio Inc Company Profile and News Bloomberg Markets

9 hours ago Bloomberg.com Show details

Company profile page for Avrobio Inc including stock price, company news, press releases, executives, board members, and contact information

Category: Contact NumberShow more

AVROBIO : Corporate Presentation June 2021 MarketScreener

9 hours ago Marketscreener.com Show details

Corporate Presentation J U N E 2 0 2 1 Disclaimer This presentation has August 5, 2021

Category: Contact NumberShow more

AVROBIO Reports Fourth Quarter and Fiscal Year 2020

3 hours ago Finance.yahoo.com Show details

AVROBIO reported a net loss of $28.1 million for the fourth quarter of 2020, and a net loss of $119.7 million for the year ended 2020, as compared to …

Category: Contact NumberShow more

University announces partnership with AVROBIO for Hunter

7 hours ago Uominnovationfactory.com Show details

161 603 7772

For more information, please contact: Roisin McCallion [email protected] +44 (0)161 603 7772 (office)* +44 (0)7552 008 131 (mobile) *As a result of lockdown related to Covid-19, office landline numbers are not currently being monitored. Therefore, please email or phone an alternative number, where possible.

Category: Contact NumberShow more

AVROBIO Announces Inducement Grants Under Nasdaq Listing

7 hours ago Finance.yahoo.com Show details

CAMBRIDGE, Mass., September 03, 2021--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced

Category: Contact NumberShow more

All Time Past 24 Hours Past Week Past month

Please leave your comments here:

Brand New Updated

Frequently Asked Questions

Who is the ceo of avrobio cell therapy?

We are AVROBIO. Geoff is a pioneer in cell and gene therapy with a track record of successful leadership at innovative biotechs. He is the former CEO of Organogenesis Inc., the world’s leading cell therapy company.

What kind of job can you get with avrobio?

Clinical Scientist will have a substantial role in protocol development, study execution, review and interpretation of scientific and clinical data and... The PV Operations Lead manages PV activities globally across all AVROBIO products in clinical development and on the market.

What makes avrobio different from other gene therapy companies?

WE ARE AVROBIO Join our team! We are all about innovation. Collaboration. Dedication. And a quality we call “smart speed” — moving thoughtfully but with urgency to bring pioneering therapies to individuals living with genetic disease.

How many patients did avrobio treat during his tenure?

During his tenure at the helm, the company treated 1 million patients with living cell therapies, received the first approval of an allogeneic cell therapy from the FDA’s Center for Biologics Evaluation and Research and led the field of regenerative medicine.

Brand New Updated

Popular Brands

Amazon
Abbvie
Aia
Asml
Att
Amgen
Apple
Adobe
Aptar
Acc
Adidas
Aak
Aes